<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00918047</url>
  </required_header>
  <id_info>
    <org_study_id>804P107</org_study_id>
    <nct_id>NCT00918047</nct_id>
  </id_info>
  <brief_title>Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients</brief_title>
  <official_title>Multiple Dose, Open-Label, Multi-Center Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of OXC XR as Adjunctive Therapy in Pediatric Subjects With Refractory Partial Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Supernus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Supernus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the pharmacokinetics, safety, and tolerability of OXC XR as adjunctive&#xD;
      therapy in pediatric subjects with refractory partial epilepsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open-label, multiple dose, multicenter study consisting of a Screening Period (up&#xD;
      to 14 days), a Dosing Period (7 days), and a Follow-up Period (7 days). In-clinic visits&#xD;
      occurred at screening, Visit 1 (Day 0), and Visit 2 (Day 7)/Early Discontinuation. All&#xD;
      subjects received open-label SPN 804O as adjunctive therapy during the Dosing Period. At&#xD;
      Visit 1, eligible subjects were assigned to 1 of 4 treatment groups (150, 300, 450, or&#xD;
      600mg/day) based on weight (15-&lt;30, 30-&lt;45, 45-&lt;60, &gt;=60kg). The Dosing Period consisted of&#xD;
      six consecutive days of a daily dose, taken at home, followed by a final day with the dose&#xD;
      taken on-site and including blood draws for PK analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Examine the steady-state pharmacokinetics (PK) of OXC XR and to assess the safety and tolerability of repeated oral dosing of OXC XR in pediatric subjects with partial seizures.</measure>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Epilepsies, Partial</condition>
  <arm_group>
    <arm_group_label>SPN-804O 150mg/Day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who weighed 15.0 to 29.9 kg dosed with SPN-804O 150mg/Day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPN-8040 300mg/Day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who weighed 30.0 to 44.9 kg dosed with SPN-8040 300mg/Day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPN-8040 450mg/Day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who weighed 45.0 to 59.9 kg dosed with SPN-8040 450mg/Day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPN-8040 600mg/Day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who weighed 60.0 kg and above dosed with SPN-8040 600mg/Day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPN-804O</intervention_name>
    <description>Open Label study</description>
    <arm_group_label>SPN-8040 300mg/Day</arm_group_label>
    <arm_group_label>SPN-8040 450mg/Day</arm_group_label>
    <arm_group_label>SPN-8040 600mg/Day</arm_group_label>
    <arm_group_label>SPN-804O 150mg/Day</arm_group_label>
    <other_name>oxcarbazepine extended-release</other_name>
    <other_name>OXC XR</other_name>
    <other_name>Oxtellar XR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to provide written informed assent (IAF), as appropriate, with written informed&#xD;
             permission (and informed consent (ICF) where required by regional laws or regulations)&#xD;
             from the parent or legally-authorized representative (LAR).&#xD;
&#xD;
          2. Male or female aged 4 to 17 years, inclusive, with a current diagnosis of partial&#xD;
             onset seizures with or without secondarily generalized seizures as confirmed by the&#xD;
             1981 and 1989 International League Against Epilepsy Classifications).&#xD;
&#xD;
          3. Currently receiving treatment with at least one and up to two anti-epileptic drugs&#xD;
             (AEDs), excluding oxcarbazepine and phenytoin. AED therapy must have been initiated&#xD;
             more than one month prior to Visit 1 and doses must be stable for at least two weeks&#xD;
             prior to Visit 1. A vagal nerve stimulator implanted for at least six months and with&#xD;
             parameters unchanged for at least one month prior to Visit 1 is allowed and not&#xD;
             considered to be an AED. Magnet use is allowed.&#xD;
&#xD;
          4. No diagnosis of a progressive neurological disorder based on previous imaging.&#xD;
&#xD;
          5. Weight within the 25 - 75 % weight-for-age percentiles based on the National Center&#xD;
             for Health Statistics Growth Charts, and not less than 15.0kg.&#xD;
&#xD;
          6. Able and willing to swallow whole tablets.&#xD;
&#xD;
          7. Females of childbearing potential (FOCP) should either be sexually inactive&#xD;
             (abstinent) for 14 days prior to the first dose, throughout the study and for four&#xD;
             days following the last dose or, if sexually active, will be using one of the&#xD;
             following acceptable birth control methods:&#xD;
&#xD;
               1. Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral&#xD;
                  oophorectomy) six months minimum;&#xD;
&#xD;
               2. Intrauterine device in place for at least three months;&#xD;
&#xD;
               3. Barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to&#xD;
                  the first dose, throughout the study and for four days following the last dose;&#xD;
&#xD;
               4. Surgical sterilization of the partner (vasectomy for six months minimum);&#xD;
&#xD;
               5. Hormonal contraceptives in addition to a barrier method (condom, diaphragm) with&#xD;
                  spermicide for at least 14 days prior to the first dose, throughout the study and&#xD;
                  for four days following the last dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A documented history of status epilepticus in the past year.&#xD;
&#xD;
          2. Seizures secondary to illicit drug or alcohol use, infection, neoplasia, demyelinating&#xD;
             disease, degenerative neurological disease, or central nervous system disease deemed&#xD;
             progressive, metabolic illness, or progressive degenerative disease.&#xD;
&#xD;
          3. Diagnosis or an electroencephalogram consistent with a diagnosis of seizure disorders&#xD;
             other than partial epilepsy.&#xD;
&#xD;
          4. Meets criteria for history of major depressive or manic episode, according to&#xD;
             Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision.&#xD;
&#xD;
          5. Any history of suicide intent and/or attempt.&#xD;
&#xD;
          6. History or presence of clinically significant, chronic medical condition, especially&#xD;
             those contraindicating antiseizure medication, (e.g., any neurological,&#xD;
             gastrointestinal, endocrine, cardiovascular, pulmonary, hematological, immunologic,&#xD;
             renal, hepatic or metabolic disease) that may affect the safety of the subject in the&#xD;
             opinion of the Investigator.&#xD;
&#xD;
          7. Use of oxcarbazepine or phenytoin within 10 days prior to first dose of SM.&#xD;
&#xD;
          8. Use of felbamate with less than 18 months of continuous exposure prior to screening.&#xD;
&#xD;
          9. Frequent need of rescue benzodiazepines (more than once in a 28 day period).&#xD;
&#xD;
         10. Use of diuretics or other sodium-lowering medications within seven days prior to first&#xD;
             dose of study medication (SM).&#xD;
&#xD;
         11. History or presence of clinically significant laboratory, electrocardiogram (ECG), or&#xD;
             vital sign abnormalities at screening that may affect the safety of the subject, in&#xD;
             the opinion of the Investigator.&#xD;
&#xD;
         12. Presence of potential hepatic function impairment as shown by, but not limited to,&#xD;
             alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 3 times the upper&#xD;
             limit of normal (ULN), or total bilirubin &gt;1.5 times ULN.&#xD;
&#xD;
         13. Presence of suspected impairment of renal function defined by serum creatinine â‰¥1.5&#xD;
             times ULN.&#xD;
&#xD;
         14. History of substance abuse or dependence.&#xD;
&#xD;
         15. Females who are pregnant or lactating.&#xD;
&#xD;
         16. Previous known hypersensitivity to OXC or other related drugs, such as carbamazepine.&#xD;
&#xD;
         17. Use of an investigational drug or device or participation in an investigational study&#xD;
             within 30 days prior to the first dose of SM.&#xD;
&#xD;
         18. Any reason which, in the opinion of the Investigator, would prevent the subject from&#xD;
             participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Loxahatchee Groves</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>June 9, 2009</study_first_submitted>
  <study_first_submitted_qc>June 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2009</study_first_posted>
  <last_update_submitted>June 29, 2017</last_update_submitted>
  <last_update_submitted_qc>June 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxcarbazepine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

